Global Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2028

  • Healthcare
  • Upcoming Report
  • Sep 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Lung Cancer Therapeutics Market, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours, Mesothelioma, Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028.

Lung Cancer Therapeutics Market Market Analysis and Insights of Lung Cancer Therapeutics Market

Data Bridge Market Research analyses that the lung cancer therapeutics market will exhibit a CAGR of around 9.91% for the forecast period of 2021-2028. Rising prevalence of cancer and other chronic disorders, increased focus on research and development proficiencies in regards to medical devices and on the adoption of advanced healthcare technologies, growing fondness for smoking especially among the youngsters and rising expenditure for the development of healthcare infrastructure development especially in the developing economies are the major factors attributable to the growth of lung cancer therapeutics market.

Lung cancer has the highest death rate among all the cancers and is the second most commonly detected among people. In lung cancer, the cancerous cells form tumour which results in decreasing the efficiency of lungs to supply oxygen to the bloodstream. Cigarette smoking, cigar smoking, and asbestos exposure are the most common causes of lung cancer.

Upsurge in the digital advertisements promoting therapeutics is one of the major factors fostering the growth of the market. Growth opportunities in emerging countries such as India, China, Brazil, and South Africa coupled with growing innovations and advancements of technologies is another market growth determinant. Rising health awareness among the individuals, surge in collaboration between pharmaceutical companies and rising medical tourism are other important factors that will further generate lucrative market growth opportunities.

However, improper and unfavourable reimbursement scenario in the developing and underdeveloped economies will derail the market growth rate. Also, high cost associated with oncology drug development will further pose challenges for the market. Dearth of skilled professionals in the backward economies and adverse effects associated with cancer therapeutics will also hamper the market growth rate.

This lung cancer therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lung cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Lung Cancer Therapeutics Market Scope and Market Size

The lung cancer therapeutics market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of cancer type, the lung cancer therapeutics market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumours, pulmonary neuroendocrine tumours and mediastinal tumours.
  • On the basis of molecule type, the lung cancer therapeutics market is segmented into small molecules and biologics.
  • On the drug class, the lung cancer therapeutics market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors and others.
  • On the basis of treatment type, the lung cancer therapeutics market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs.
  • On the basis of therapy type, the lung cancer therapeutics market is segmented into single drug therapy and combination therapy.
  • On the basis of end user, the lung cancer therapeutics market is segmented into hospitals, specialty clinics, homecare and others.
  • On the basis of distribution channel, the lung cancer therapeutics market is segmented into hospital pharmacy, retail pharmacy, online and others.

Lung Cancer Therapeutics Market Country Level Analysis

The lung cancer therapeutics market is analysed and market size insights and trends are provided by country, cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel as referenced above.

The countries covered in the lung cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the lung cancer therapeutics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the increasing funding for research and development activities and growing adoption of advanced lung cancer therapeutics. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period owing to the growing prevalence of lung cancer, increasing consumption of tobacco and ever-rising geriatric population.

The country section of the lung cancer therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The lung cancer therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lung cancer therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer therapeutics market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Lung Cancer Therapeutics Market Share Analysis

The lung cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to lung cancer therapeutics market.

The major players covered in the lung cancer therapeutics market report are Church & Dwight Co., Inc., GlaxoSmithKline plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company., AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., CELGENE CORPORATION, Sanofi, Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd. and Bristol-Myers Squibb Company among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Customization Available : Global Lung Cancer Therapeutics Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions